Radiopharm Theranostics (ASX: RAD) to present at healthcare events by B. Riley Securities

May 08, 2024 01:05 AM PDT | By Team Kalkine Media

Google News:

Radiopharm Theranostics (ASX: RAD) to present at healthcare events by B. Riley Securities — Image source: Company update

Recent News

Purple Pepe listed on major crypto exchanges, enters US real estate ma...

US considers deal to let UAE import over a million advanced Nvidia chi...

Brazil inks ethanol byproduct export deal with China, targets US feed...

Trump in Saudi Arabia: Riyadh pledges $600 billion investment in US

Highlights

RAD is set to gain the spotlight in industry gatherings by B. Riley Securities.

The focus will be on radiopharma, brain cancer and cell therapies.

CEO Riccardo Canevari to lead discussion on brain tumor advancements.

Radiopharm Theranostics (ASX: RAD), a developer of innovative radiopharmaceutical products, is set to take center stage at a series of healthcare events hosted by B. Riley Securities this May. These events, focusing on radiopharma, brain cancer, and cell therapies, will provide a platform for Radiopharm to showcase its groundbreaking technologies and future prospects.

With both in-person gatherings in New York and virtual presentations, Radiopharm's board members and management team will engage with industry professionals and institutional investors, highlighting the company's world-class platform for both diagnostic and therapeutic applications. CEO and Managing Director, Riccardo Canevari, will participate in a panel discussion titled "New DAWN for Brain Tumors," further underscoring Radiopharm's commitment to advancing treatments for challenging medical conditions.

This event comes at a pivotal time for the radiopharmaceutical industry, with heightened interest and significant merger and acquisition activity. Radiopharm says that it aims to leverage this momentum, positioning itself as an emerging leader in the field. Mr. Canevari expressed enthusiasm about the opportunity, stating, "We look forward to the opportunity to be featured so prominently throughout this series of events."

Radiopharm's participation underscores its dedication to driving innovation and delivering impactful solutions in healthcare. Amid growing demand for advanced diagnostic and therapeutic options, the company believes that its cutting-edge platform holds promise for addressing unmet medical needs and improving patient outcomes.

The company's presence at these events not only highlights its technological advancements but also signals its growing foothold in the rapidly evolving healthcare sector. With its compelling vision and momentum, the company is advancing to make significant strides in revolutionising the field of radiopharmaceuticals, ultimately benefiting patients worldwide.

Shares of RAD last traded on Wednesday (08 May) at AU$0.038.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.